Grant: CIHR Fellowship
Direct Payment
$125,000.00
Understanding and Resolving Dysregulated Collagen-I Proteostasis Linked to Osteogenesis Imperfecta
FY 2015-16
Summary
Osteogenesis imperfecta (OI), an inherited disease, occurs in approximately one out of every 15,000-20,000 births. There is currently no cure for OI. The key pathological mechanism underpinning OI is a failure of bone cells to produce a sufficient level of high quality collagen-I, which plays a crucial role in bone formation. I hypothesize that new biochemical methods regulating the amount and quality of collagen-I produced by cells could one day lead to treatment strategies that address the underlying causes of OI. Before I can achieve this goal, I must first understand the fundamental processes of healthy and pathologic collagen-I production. During the course of this fellowship, I will answer the following questions: (1) Which intracellular proteins differentially interact with and engage healthy and pathologic collagen-I? (2) Which proteins regulate the production of high quality collagen-I? and (3) How can we control adaptive cellular responses to help cells produce more high quality collagen-I? I will first use state-of-the-art mass spectrometry methods to identify a working list of proteins interacting with healthy and pathologic collagen-I. Follow-up biochemical experiments will allow me to (1) validate my findings and (2) identify potential targets for beneficial effects. I will also use our lab's novel technologies to selectively modulate the activity of cellular adaptive responses to resolve misbehaving collagen problems. My established cellular platforms, along with cells isolated from OI patients, will be used in this study. Important cell-based findings will be transferred to mouse models to investigate whether targeting identified important pathways will have beneficial effects in vivo. Success in these studies will make a considerable contribution to our understanding of collagen-I proteostasis. In addition, findings from this study could enable the development of transformative, mechanism-based treatments for OI and other collagen-related diseases.
Department
Program
CIHR Fellowship
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
339292
Name
Doan Ngoc Duc
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Understanding and Resolving Dysregulated Collagen-I Proteostasis Linked to Osteogenesis Imperfecta
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$125,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Biochemistry And Chemical Biology; Collagen-I; Endoplasmid Reticulum Protein Folding Environment; Extracellular Matrix; Molecular Mechanism; Osteogenegis Imperfecta; Protein Folding And Misfolding; Protein Homeostasis Network; Tmt-Assisted Mass Spectrometry; Unfolded Protein Response
Abstract
Osteogenesis imperfecta (OI), an inherited disease, occurs in approximately one out of every 15,000-20,000 births. There is currently no cure for OI. The key pathological mechanism underpinning OI is a failure of bone cells to produce a sufficient level of high quality collagen-I, which plays a crucial role in bone formation. I hypothesize that new biochemical methods regulating the amount and quality of collagen-I produced by cells could one day lead to treatment strategies that address the underlying causes of OI. Before I can achieve this goal, I must first understand the fundamental processes of healthy and pathologic collagen-I production. During the course of this fellowship, I will answer the following questions: (1) Which intracellular proteins differentially interact with and engage healthy and pathologic collagen-I? (2) Which proteins regulate the production of high quality collagen-I? and (3) How can we control adaptive cellular responses to help cells produce more high quality collagen-I? I will first use state-of-the-art mass spectrometry methods to identify a working list of proteins interacting with healthy and pathologic collagen-I. Follow-up biochemical experiments will allow me to (1) validate my findings and (2) identify potential targets for beneficial effects. I will also use our lab's novel technologies to selectively modulate the activity of cellular adaptive responses to resolve misbehaving collagen problems. My established cellular platforms, along with cells isolated from OI patients, will be used in this study. Important cell-based findings will be transferred to mouse models to investigate whether targeting identified important pathways will have beneficial effects in vivo. Success in these studies will make a considerable contribution to our understanding of collagen-I proteostasis. In addition, findings from this study could enable the development of transformative, mechanism-based treatments for OI and other collagen-related diseases.
Competitiondate
201511
Approvedterm2
2 yrs 6 mths
Pinamesdelim
Doan, Ngoc Duc
Approvedterm
2 ans 6 mois
Cihrcontribution2
~ $125,000~ $0~